Listen on: Apple Podcasts | Spotify | Amazon Music | Podcast Index | Overcast | YouTube

You’ve just had a baby, you’re holding this tiny new human, and a nurse walk in and says, “Time for the hepatitis B vaccine.” For over 30 years, that’s been standard for almost every newborn in America. But in December 2025, a federal vaccine advisory committee voted to change this guidance, sparking confusion, concern, and debate among parents and healthcare professionals alike.

A Note on This Article

This is the first time I’ve waded into a current controversy with potential political overtones. Typically, I avoid such topics—that’s not what this podcast or blog is about. However, I felt this particular issue warranted an exception. The discussion around the hepatitis B vaccine has quickly drifted away from the actual evidence, and I’ve heard from many listeners who feel confused or overwhelmed by the headlines.

This controversy has many evidence-based elements that should be considered, which is exactly where my strength lies: reading and interpreting the scientific literature so you don’t have to. I genuinely value your feedback on whether I should tackle similar topics when they surface. Should I weigh in when health issues become politicized but still have a strong evidence base? What other topics would you like me to cover? Your input really shapes the direction of this work, so please let me know.

Why This Matters

Hepatitis B is a virus that attacks the liver, and for infants, the stakes are extraordinarily high. When babies contract hepatitis B at birth or during the first few months of life, approximately 90% develop lifelong chronic infection—a stark contrast to the roughly 5% chronicity rate in adults. Chronic hepatitis B can lead to cirrhosis, liver failure, and liver cancer decades later, with about 25% of those infected during childhood dying prematurely from these complications.

Before universal newborn vaccination began in 1991, roughly 18,000 to 20,000 U.S. children became infected every year. Today, that number has plummeted to fewer than 20 annual cases among young people—a stunning 95-99% reduction. This dramatic success story is precisely what makes the recent policy change so contentious.

What Changed?

In December 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted 8-3 to recommend “individual-based decision-making” for the hepatitis B birth dose. Under the new guidance, if the mother tests positive for hepatitis B or her status is unknown, the baby still gets the birth dose. However, if the mother tests negative, parents may now wait until two months for the first dose after discussing options with their doctor.

This represents a major shift away from the universal approach that has been in place for over three decades. The recommendation still requires approval from the CDC director before taking effect, and notably, the American Academy of Pediatrics has already stated they will continue recommending the birth dose for all newborns.

A Controversial Process

What raised eyebrows among many public health experts wasn’t just what changed, but how. The committee was reconstituted with many long-standing expert members removed and several new members added, including individuals without medical or scientific backgrounds. Some participants were known for vaccine skepticism, and their presentations didn’t always reflect scientific consensus.

Critically, there were no new safety concerns, no new adverse event signals, and no new evidence showing harm from giving newborns the vaccine. Instead, arguments centered on the current low rate of hepatitis B in U.S. infants, parental autonomy, and the belief that maternal testing alone is reliable enough to skip universal birth dosing.

CDC scientists, pediatric infectious disease experts, and public health organizations strongly disagreed. As ACIP member Dr. H. Cody Meissner stated during the proceedings, “We are doing harm by changing this wording.” Public health leaders warned that reducing coverage, even slightly, could lead to preventable infections.

Understanding the Real Risks

Some might think, “Hepatitis B is a sexually transmitted disease—why would my baby need this?” But mother-to-child transmission during birth isn’t the only risk. Young children can be exposed through bites that break the skin, open sores, contact with tiny amounts of infected blood, or shared household items like toothbrushes, razors, and nail clippers. The hepatitis B virus can survive on surfaces for up to a week, and you may not know who in your broader family or childcare circle has chronic hepatitis B. The CDC estimates that about half of the 640,000 to 1.89 million Americans with chronic hepatitis B don’t know they’re infected.

Two Key Concerns About Delaying

The first concern is infection during those first two months. While it’s a short window and the risk is low, if a baby does get infected early, the consequences are lifelong. The birth dose protects against the unexpected: a misrecorded maternal test, a missed test, or an unrecognized household exposure.

The second, larger concern is whether babies will actually get vaccinated at two months. Right now, the birth dose ensures nearly universal coverage because the baby is right there, the healthcare team is present, and there’s minimal friction. Moving the first dose to two months introduces obstacles: missed appointments, parental hesitancy, logistical challenges, and mixed messages from social media. Even today, about 9% of parents delay or skip the hepatitis B vaccine. A policy that makes delay the default will almost certainly increase the number of unvaccinated children.

Addressing Autism Concerns

Vaccine discussions inevitably raise autism concerns, and parents deserve real answers. The evidence is consistent that vaccines don’t cause autism. This conclusion is backed by numerous large studies involving hundreds of thousands of children, reviews by major scientific bodies, and research specifically examining the hepatitis B vaccine, MMR vaccine, and vaccine ingredients like thimerosal and aluminum.

Recent autism diagnoses have increased, but this is most likely due to broader diagnostic criteria, better awareness, improved screening, and environmental factors unrelated to vaccines. O The preponderance of scientific evidence finds no link between hepatitis B vaccination and autism or other neurodevelopmental disorders.

Where the Evidence Leads

If I were designing national policy, I would keep the universal birth dose. The vaccine is safe—there’s no new evidence suggesting otherwise. It works extraordinarily well. And most importantly, the proof is in the pudding: infant hepatitis B infections are rare precisely because the current system is simple and effective.

That said, this change isn’t catastrophic. Parents can still choose the birth dose, hospitals can still offer it, and pediatricians can still recommend it. Most babies whose mothers are hepatitis B negative remain at very low risk.

Advice for Parents

Know your own hepatitis B status and ensure it’s documented correctly. Strongly consider the birth dose, even if you test negative. If you decide to delay, commit absolutely to the two-month appointment. And most importantly, rely on your doctor, not social media, for guidance.

Public health works best when decisions are evidence-based. The hepatitis B birth dose is one of our most successful public health interventions. While the recommendation may be shifting, maintaining universal newborn vaccination remains the safest choice for protecting our children against a preventable disease with potentially devastating consequences.